Trinity Biotech

Trinity Biotech FCF Yield

The Free Cash Flow Yield of Trinity Biotech (TRIB) as of Nov 10, 2026 is -84.70 %. In the previous year, Free Cash Flow Yield was -99.36 % — a change of -14.75% (higher).

FCF Yield

-84.70 %

YoY

-14.75%

Last updated:

Free Cash Flow Yield of Trinity Biotech is 2025 -84.70 % . Free Cash Flow Yield of Trinity Biotech was 2024 -99.36 % . It decreases by -14.75% higher compared to the previous year.

The Trinity Biotech FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-72.15 USD
Jan 1, 2019
-68.87 USD
Jan 1, 2020
94.50 USD
Jan 1, 2021
31.69 USD
Jan 1, 2022
-48.08 USD
Jan 1, 2023
-86.15 USD
Jan 1, 2024
-99.36 USD
Jan 1, 2025
-84.70 USD
The Trinity Biotech FCF Yield history
YEARFCF YieldYoY
-84.70 %-14.75%
-99.36 %+15.33%
-86.15 %+79.18%
-48.08 %-251.70%
31.69 %-66.46%
94.50 %-237.20%
-68.87 %-4.54%
-72.15 %+143.27%
-29.66 %-49.98%
-59.29 %-18.06%
-72.36 %+26.83%
-57.05 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Free Cash Flow Yield of Trinity Biotech is -84.70 % in 2025.

Free Cash Flow Yield of Trinity Biotech changed from -99.36 % to -84.70 %, representing a -14.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Trinity Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Trinity Biotech

All Key Metrics — Trinity Biotech